Comerica Bank Gilead Sciences, Inc. Transaction History

Comerica Bank

$23.8 Billion
Q2 2024

A detailed history of Comerica Bank transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Comerica Bank holds 323,358 shares of GILD stock, worth $28.5 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

323,358

Previous 332,394 2.72%

Holding current value

$28.5 Million

Previous $24.3 Million 8.88%

% of portfolio

0.09%

Previous 0.11%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$63.15 - $72.88 $570,623 - $658,543	-9,036 Reduced 2.72%	323,358 $22.2 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $172,078 - $209,845	2,404 Added 0.73%	332,394 $24.3 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $2.33 Million - $2.65 Million	31,849 Added 10.68%	329,990 $26.7 Million
Q3 2023 Nov 21, 2023	SELL	$73.94 - $80.67 $4.78 Million - $5.22 Million	-64,687 Reduced 17.83%	298,141 $22.3 Million
Q2 2023 Aug 22, 2023	BUY	$76.01 - $86.7 $6.27 Million - $7.15 Million	82,442 Added 29.4%	362,828 $80,000
Q4 2022 Jan 26, 2023	SELL	$62.32 - $89.47 $33,777 - $48,492	-542 Reduced 0.19%	280,386 $0
Q3 2022 Oct 28, 2022	BUY	$59.54 - $68.01 $405,646 - $463,352	6,813 Added 2.49%	280,928 $19.4 Million
Q2 2022 Aug 02, 2022	BUY	$57.72 - $65.01 $1.1 Million - $1.24 Million	19,064 Added 7.47%	274,115 $17 Million
Q1 2022 Apr 27, 2022	SELL	$57.92 - $72.58 $686,294 - $860,000	-11,849 Reduced 4.44%	255,051 $15.2 Million
Q4 2021 Feb 18, 2022	SELL	$64.88 - $73.64 $351,584 - $399,055	-5,419 Reduced 1.99%	266,900 $19.4 Million
Q3 2021 Nov 22, 2021	SELL	$67.69 - $73.03 $3.58 Million - $3.86 Million	-52,876 Reduced 16.26%	272,319 $19 Million
Q2 2021 Aug 26, 2021	SELL	$63.47 - $69.35 $1.78 Million - $1.95 Million	-28,106 Reduced 7.96%	325,195 $22.4 Million
Q1 2021 Apr 28, 2021	BUY	$60.0 - $68.46 $359,940 - $410,691	5,999 Added 1.73%	353,301 $22.8 Million
Q4 2020 Jan 28, 2021	SELL	$56.65 - $64.55 $1.2 Million - $1.36 Million	-21,132 Reduced 5.74%	347,302 $20.2 Million
Q3 2020 Oct 30, 2020	SELL	$62.1 - $78.08 $639,381 - $803,911	-10,296 Reduced 2.72%	368,434 $23.3 Million
Q2 2020 Jul 31, 2020	BUY	$72.34 - $84.0 $1.22 Million - $1.42 Million	16,858 Added 4.66%	378,730 $29.1 Million
Q1 2020 May 01, 2020	SELL	$62.63 - $80.22 $89,435 - $114,554	-1,428 Reduced 0.39%	361,872 $27.1 Million
Q4 2019 Feb 07, 2020	SELL	$61.62 - $67.78 $157,623 - $173,381	-2,558 Reduced 0.7%	363,300 $23.6 Million
Q3 2019 Oct 31, 2019	BUY	$62.51 - $69.0 $1.04 Million - $1.14 Million	16,565 Added 4.74%	365,858 $23.2 Million
Q2 2019 Aug 02, 2019	SELL	$61.87 - $69.38 $3.89 Million - $4.36 Million	-62,859 Reduced 15.25%	349,293 $0
Q1 2019 May 02, 2019	SELL	$62.53 - $70.05 $1.96 Million - $2.2 Million	-31,348 Reduced 7.07%	412,152 $0
Q4 2018 Feb 06, 2019	SELL	$60.54 - $79.0 $4.41 Million - $5.76 Million	-72,887 Reduced 14.11%	443,500 $30.9 Million
Q3 2018 Nov 01, 2018	SELL	$71.28 - $78.92 $2.29 Million - $2.54 Million	-32,181 Reduced 5.87%	516,387 $37 Million
Q2 2018 Aug 01, 2018	SELL	$64.88 - $75.68 $1.33 Million - $1.55 Million	-20,544 Reduced 3.61%	548,568 $42.3 Million
Q1 2018 May 01, 2018	SELL	$72.84 - $88.8 $2.62 Million - $3.2 Million	-36,026 Reduced 5.95%	569,112 $42.4 Million
Q4 2017 Feb 02, 2018	SELL	$71.15 - $83.52 $5 Million - $5.87 Million	-70,308 Reduced 10.41%	605,138 $49.2 Million
Q3 2017 Nov 06, 2017	BUY	$72.11 - $85.47 $48.7 Million - $57.7 Million	675,446	675,446 $51.3 Million

Others Institutions Holding GILD

# of Institutions

1,893

Shares Held

1.02B

Call Options Held

12M

Put Options Held

9.04M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.

Account